Search Results - dc5bxx

66 Results

Sort By:

Mononegavirales Vectors Expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...

Published: 7/25/2024 | Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir

Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use

Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread....

Published: 7/25/2024 | Inventor(s): Shirin Munir, Cindy Luongo, Peter Collins, Cyril Le Nouen, Xueqiao Liu, Ursula Buchholz

Keywords(s): 2, ACUTE, Attenuated, B/HPIV3, BOVINE/HUMAN, chimeric, CORONAVIRUS, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, GLYCOPROTEIN, PIV3, respiratory, S, SARS-CoV-2, SEVERE, spike, Syndrome

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Research Materials

Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene

RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with...

Published: 7/25/2024 | Inventor(s): Cyril Le Nouen, Ursula Buchholz, Peter Collins

Keywords(s): ADDITIONAL, BEARING, Codonpair, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deoptimized, DXXXXX, GENES, Improved, Live-Attenuated, M, Mutations, N, NS1, NS2, P, Pgene, POINT, respiratory, RSV, SH, Syncytial, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Prefusion Coronavirus Spike Proteins and Their Use

Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Michael Joyce, Kizzmekia Corbett, Hadi Yassine, Jason McLellan, Christopher Cottrell, Nianshuang Wang, Jesper Pallesen, Hannah Turner, Robert Kirchdoerfer, Andrew Ward, Barney Graham

Keywords(s): CORONAVIRUS, DC5BXX, proteins, Stabilized, VACCINATION

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines

Mononegavirales Vectors expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...

Published: 7/25/2024 | Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease

Protein Nanoparticles for Antigen Display in Vaccines

The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to...

Published: 7/25/2024 | Inventor(s): Dustin McCraw, Audray Harris

Keywords(s): ANTIGEN, DC5BXX, DISPLAY, INFLUENZA, Nanoparticles, Protein, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, Application > Vaccines, TherapeuticArea > Infectious Disease

A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines

Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines...

Published: 7/25/2024 | Inventor(s): Roger Glass, Jean-Francois Saluzzo, Baoming Jiang

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Inactivation, Listed LPM Surabian as of 4/15/2015, NCIRD, OID-NCIRD-DVD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rotavirus, thermal

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Therapeutics

Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2

Herpes simplex viral infections, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes,...

Published: 7/25/2024 | Inventor(s): Jesse Arbuckle, Thomas Kristie

Keywords(s): DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DEXXXX, DXXXXX, EZH1/2, HERPESVIRUS, Infection, Inhibitors, Latency, Listed LPM Fenn as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reactivation, Suppresses, VLXXXX, WKXXXX, WNXXXX, XKXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Novel Epstein-Barr Virus Vaccines

Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection. The...

Published: 7/25/2024 | Inventor(s): Wei Bu, Gary Nabel, Jeffrey Cohen, Masaru Kanekiyo

Keywords(s): D, DC5BXX, Development, EPSTEIN-BARR, Evelopment, Listed LPM Chang as of 4/15/2015, Nanoparticle-Based, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, vaccines, VCXXXX, virus, VLXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Vaccines

Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines

CDC researchers have developed a potent immunogenic enhancer polypeptide useful for improving flavivirus vaccines. Flaviviruses such as dengue virus (1, 2, 3 and 4), Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, yellow fever virus and tick-borne encephalitis virus are a great burden on public health. ...

Published: 7/25/2024 | Inventor(s): Holly Hughes, Gwong-Jen Chang

Keywords(s): ADJUSTMENT, adjuvant, Adjuvant-like, BCXXXX, Boost, BOOSTING, CD4, CDC Docket Import, CDC Docket Import CDC Prosecuting, Cell, DB4BXX, DB4XXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DENGUE FEVER, Dengue Vaccine, Dengue-1, Dengue-2, Dengue-Like, DXXXXX, Epitope, Flavivirus, FLAVIVIRUSES, Identification, in vivo, JAPANESE ENCEPHALITIS VIRUS, Listed LPM Houze as of 4/15/2015, Mosquito, Mosquitoes, Nile, OID-NCEZID-DVBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMER, T, THEREOF, Tick-Bone, TICK-BORNE, UBXXXX, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VBXXXX, Vector-borne, Vector-borne diseases, virus, VLXXXX, VOXXXX, WAXXXX, West, WIXXXX, WJXXXX, WMXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, Application > Therapeutics, Application > Research Materials, Application > Consumer Products, TherapeuticArea > Infectious Disease

1 2 3 4 5 6 7